{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:09:19Z","timestamp":1785470959841,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Facial angiofibroma is the most predominant cutaneous manifestation of tuberous sclerosis complex (TSC), a rare autosomal dominant genetic disorder impacting the mechanistic target of rapamycin (mTOR). Facial angiofibroma can bleed spontaneously, impair eyesight, and cause aesthetic disfiguration causing psychological and social stress. To date, there is little or no evidence on the demographics, and other TSC features associated with facial angiofibroma or the use of mTOR inhibitor for the management of facial angiofibroma. This is a retrospective study of TSC Alliance\u2019s Natural History Database aimed to characterize facial angiofibroma and to evaluate features associated with a higher risk of facial angiofibroma or the use of topical mTOR inhibitors for the\u00a0management of facial angiofibroma. Data in the NHD was obtained from 18 clinical sites in the US since 2006.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 2240 patients, 2088 patients were enrolled in the US and data from 2057 patients were included in this analysis. The mean (median) age of overall TSC patients was 22.4 (19.0) years. A total of 69 patients were\u2009\u2264\u20095\u00a0years of age. Facial angiofibroma was noted in 1329 (64.6%) patients with TSC. Patients with facial angiofibroma were older on average (Mean: 25.9 [median, 23.0] vs. 16.0 [12.4\u00a0years] years, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). In patients with vs. without facial angiofibroma, <jats:italic>TSC2<\/jats:italic> mutation (38.9% vs. 34.8%) was more common than <jats:italic>TSC1<\/jats:italic> mutation (12.3% vs. 18.1%), and the incidence rate of most of the other TSC-related manifestations was significantly higher in patients with facial angiofibroma. Majority of patients had focal seizures (72.8% vs. 60.7%), followed by angiomyolipoma (63.7% vs. 21.8%) and renal cysts (59.4% vs. 33.5%). The age groups, 11\u201317 (odds ratio [OR], 2.53) and 18\u201345\u00a0years (5.98), <jats:italic>TSC2<\/jats:italic> mutation (1.31), focal seizures (1.50), ADHD (1.47) angiomyolipoma (2.79), and renal cysts (2.63) were significantly associated with a higher risk of facial angiofibroma based on multivariate logistic regression. Abrasive or laser therapy was used by 17.1% and 2.6% patients, respectively. Topical mTOR inhibitor use was noted for 329 (24.8%) patients with facial angiofibroma. Overall systemic mTOR inhibitor use was observed in 399 (30.0%) patients for management of one or more TSC manifestations. Use of systemic mTOR inhibitor for facial angiofibroma was noted for 163 (12.3%) patients, among whom only 9 (0.7%) patients used exclusively for the management of facial angiofibroma. Of the patients with facial angiofibroma, 44.6% did not receive any treatment. Significantly higher use of topical mTOR inhibitor was associated with the 11\u201317\u00a0years age group (OR, 1.67), anxiety (1.57), angiomyolipoma (1.51), and renal cysts (1.33).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The presence of <jats:italic>TSC2<\/jats:italic> mutations and most other TSC-related manifestations was significantly higher in patients with facial angiofibroma. About one-fourth of patients with facial angiofibroma used a topical mTOR inhibitor and use of systemic mTOR inhibitor for the management of facial angiofibroma or for the other manifestations was noted for 30.0%. About 44.6% of patients did not receive any treatment for the management of facial angiofibroma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02496-2","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T19:03:43Z","timestamp":1663182223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3635-6888","authenticated-orcid":false,"given":"Sreedevi","family":"Boggarapu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Roberds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnne","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Beresford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"2496_CR1","doi-asserted-by":"publisher","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","volume":"2","author":"EP Henske","year":"2016","unstructured":"Henske EP, J\u00f3\u017awiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035.","journal-title":"Nat Rev Dis Primers"},{"key":"2496_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1590\/abd1806-4841.20186972","volume":"93","author":"LKL Portocarrero","year":"2018","unstructured":"Portocarrero LKL, Quental KN, Samorano LP, Oliveira ZNP, Rivitti-Machado MCDM. Tuberous sclerosis complex: review based on new diagnostic criteria. An Bras Dermatol. 2018;93:323\u201331.","journal-title":"An Bras Dermatol"},{"key":"2496_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Northrup H, Group ITSCC. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:255\u201365.","journal-title":"Pediatr Neurol"},{"key":"2496_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","volume":"615","author":"JP Osborne","year":"1991","unstructured":"Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125\u20137.","journal-title":"Ann N Y Acad Sci"},{"key":"2496_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaad.2007.05.004","volume":"57","author":"RA Schwartz","year":"2007","unstructured":"Schwartz RA, Fern\u00e1ndez G, Kotulska K, J\u00f3\u017awiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol. 2007;57:189\u2013202.","journal-title":"J Am Acad Dermatol"},{"key":"2496_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1494","volume":"37","author":"K Inoki","year":"2005","unstructured":"Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19\u201324.","journal-title":"Nat Genet"},{"key":"2496_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0888-7543(90)90454-3","volume":"6","author":"M Smith","year":"1990","unstructured":"Smith M, Smalley S, Cantor R, Pandolfo M, Gomez MI, Baumann R, et al. Mapping of a gene determining tuberous sclerosis to human chromosome 11q14-11q23. Genomics. 1990;6:105\u201314.","journal-title":"Genomics"},{"key":"2496_CR8","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/jamadermatol.2014.938","volume":"150","author":"JM Teng","year":"2014","unstructured":"Teng JM, Cowen EW, Wataya-Kaneda M, Gosnell ES, Witman PM, Hebert AA, et al. Dermatologic and dental aspects of the 2012 international tuberous sclerosis complex consensus statements. JAMA Dermatol. 2014;150:1095\u2013101.","journal-title":"JAMA Dermatol"},{"key":"2496_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ad.2012.11.020","volume":"105","author":"R Salido-Vallejo","year":"2014","unstructured":"Salido-Vallejo R, Garnacho-Saucedo G, Moreno-Gim\u00e9nez JC. Current options for the treatment of facial angiofibromas. Actas Dermosifiliogr. 2014;105:558\u201368.","journal-title":"Actas Dermosifiliogr"},{"key":"2496_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381:125\u201332.","journal-title":"Lancet"},{"key":"2496_CR11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:817\u201324.","journal-title":"Lancet"},{"key":"2496_CR12","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388:2153\u201363.","journal-title":"Lancet"},{"key":"2496_CR13","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595\u2013606.","journal-title":"N Engl J Med"},{"key":"2496_CR14","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jaad.2015.07.018","volume":"73","author":"N Nathan","year":"2015","unstructured":"Nathan N, Wang JA, Li S, Cowen EW, Haughey M, Moss J, et al. Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus. J Am Acad Dermatol. 2015;73:802\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2496_CR15","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.3390\/ijerph18094907","volume":"18","author":"M Sugalska","year":"2021","unstructured":"Sugalska M, Tomik A, J\u00f3\u017awiak S, Werner B. Treatment of cardiac rhabdomyomas with mTOR inhibitors in children with tuberous sclerosis complex-a systematic review. Int J Environ Res Public Health. 2021;18(9):4907.","journal-title":"Int J Environ Res Public Health"},{"key":"2496_CR16","unstructured":"Highlights of prescribing information.\u00a0Rapamune. [28 June 2022]. Available from: RAPAMUNE (sirolimus) Label (fda.gov) (Accessed on 21 Jul 2022)."},{"key":"2496_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJMoa1204166","volume":"367","author":"S Euvrard","year":"2012","unstructured":"Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367:329\u201339.","journal-title":"N Engl J Med"},{"key":"2496_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamadermatol.2018.0464","volume":"154","author":"MK Koenig","year":"2018","unstructured":"Koenig MK, Bell CS, Hebert AA, Roberson J, Samuels JA, Slopis JM, et al. Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the treatment randomized clinical trial. JAMA Dermatol. 2018;154:773\u201380.","journal-title":"JAMA Dermatol"},{"key":"2496_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jamadermatol.2018.1408","volume":"154","author":"M Wataya-Kaneda","year":"2018","unstructured":"Wataya-Kaneda M, Ohno Y, Fujita Y, Yokozeki H, Niizeki H, Ogai M, et al. Sirolimus gel treatment vs placebo for facial angiofibromas in patients with tuberous sclerosis complex: a randomized clinical trial. JAMA Dermatol. 2018;154:781\u20138.","journal-title":"JAMA Dermatol"},{"key":"2496_CR20","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s13555-020-00387-7","volume":"10","author":"M Wataya-Kaneda","year":"2020","unstructured":"Wataya-Kaneda M, Nagai H, Ohno Y, Yokozeki H, Fujita Y, Niizeki H, et al. Safety and efficacy of the sirolimus gel for tsc patients with facial skin lesions in a long-term, open-label, extension, uncontrolled clinical trial. Dermatol Ther. 2020;10:635\u201350 (Heidelberg).","journal-title":"Dermatol Ther"},{"key":"2496_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaad.2017.04.005","volume":"77","author":"N Malissen","year":"2017","unstructured":"Malissen N, Vergely L, Simon M, Roubertie A, Malinge MC, Bessis D. Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: a prospective study of 25 patients. J Am Acad Dermatol. 2017;77:464-72.e3.","journal-title":"J Am Acad Dermatol"},{"key":"2496_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13023-020-01417-5","volume":"15","author":"T Hatano","year":"2020","unstructured":"Hatano T, Ohno Y, Imai Y, Moritake J, Endo K, Tamari M, et al. Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex. Orphanet J Rare Dis. 2020;15:133.","journal-title":"Orphanet J Rare Dis"},{"key":"2496_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA, Group ITSCC. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 iinternational tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:243\u201354.","journal-title":"Pediatr Neurol"},{"key":"2496_CR24","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1542\/peds.2010-0192","volume":"127","author":"BA Staley","year":"2011","unstructured":"Staley BA, Vail EA, Thiele EA. Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs. Pediatrics. 2011;127:e117\u201325.","journal-title":"Pediatrics"},{"key":"2496_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13023-019-1258-3","volume":"15","author":"JP Z\u00f6llner","year":"2020","unstructured":"Z\u00f6llner JP, Franz DN, Hertzberg C, Nabbout R, Rosenow F, Sauter M, et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare Dis. 2020;15:23.","journal-title":"Orphanet J Rare Dis"},{"key":"2496_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jamadermatol.2018.0465","volume":"154","author":"TN Darling","year":"2018","unstructured":"Darling TN. Topical sirolimus to treat tuberous sclerosis complex (TSC). JAMA Dermatol. 2018;154:761\u20132.","journal-title":"JAMA Dermatol"},{"key":"2496_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","volume":"123","author":"H Northrup","year":"2021","unstructured":"Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021;123:50\u201366.","journal-title":"Pediatr Neurol"},{"key":"2496_CR28","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1016\/j.transproceed.2009.06.227","volume":"41","author":"A Tarasewicz","year":"2009","unstructured":"Tarasewicz A, Debska-Slizie\u0144 A, Konopa J, Zdrojewski Z, Rutkowski B. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc. 2009;41:3677\u201382.","journal-title":"Transplant Proc"},{"key":"2496_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2133.2008.08677.x","volume":"159","author":"GF Hofbauer","year":"2008","unstructured":"Hofbauer GF, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, W\u00fcthrich RP, et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol. 2008;159:473\u20135.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2496_CR30","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1159\/000510222","volume":"237","author":"CC Wei","year":"2020","unstructured":"Wei CC, Hsiao YP, Gau SY, Wu YT, Wu CT, Wu MH, et al. The efficacy of everolimus for facial angiofibromas in tuberous sclerosis complex patients treated for renal angiomyolipoma\/subependymal giant cell astrocytoma. Dermatology. 2020;237(3):444\u20139. https:\/\/doi.org\/10.1159\/000510222.","journal-title":"Dermatology"},{"key":"2496_CR31","doi-asserted-by":"publisher","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","volume":"6","author":"SL Dabora","year":"2011","unstructured":"Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ, Miles D, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS ONE. 2011;6:e23379.","journal-title":"PLoS ONE"},{"key":"2496_CR32","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jdermsci.2019.05.002","volume":"94","author":"K Kitayama","year":"2019","unstructured":"Kitayama K, Maeda S, Nakamura A, Katayama I, Wataya-Kaneda M. Efficiency of sirolimus delivery to the skin is dependent on administration route and formulation. J Dermatol Sci. 2019;94:350\u20133.","journal-title":"J Dermatol Sci"},{"key":"2496_CR33","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","volume":"146","author":"AK Haemel","year":"2010","unstructured":"Haemel AK, O\u2019Brian AL, Teng JM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146:715\u20138.","journal-title":"Arch Dermatol"},{"key":"2496_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","volume":"12","author":"MK Koenig","year":"2012","unstructured":"Koenig MK, Hebert AA, Roberson J, Samuels J, Slopis J, Woerner A, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D. 2012;12:121\u20136.","journal-title":"Drugs R D"},{"key":"2496_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","volume":"153","author":"M Wataya-Kaneda","year":"2017","unstructured":"Wataya-Kaneda M, Nakamura A, Tanaka M, Hayashi M, Matsumoto S, Yamamoto K, et al. Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial. JAMA Dermatol. 2017;153:39\u201348.","journal-title":"JAMA Dermatol"},{"key":"2496_CR36","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jaad.2018.10.070","volume":"80","author":"S Leducq","year":"2019","unstructured":"Leducq S, Giraudeau B, Tavernier E, Maruani A. Topical use of mammalian target of rapamycin inhibitors in dermatology: a systematic review with meta-analysis. J Am Acad Dermatol. 2019;80:735\u201342.","journal-title":"J Am Acad Dermatol"},{"key":"2496_CR37","doi-asserted-by":"publisher","first-page":"2329048X1983504","DOI":"10.1177\/2329048X19835047","volume":"6","author":"MC Wheless","year":"2019","unstructured":"Wheless MC, Takwi AA, Almoazen H, Wheless JW. Long-term exposure and safety of a novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex: results from a single-center Open-Label Trial. Child Neurol Open. 2019;6:2329048X19835047.","journal-title":"Child Neurol Open."},{"key":"2496_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1905768","author":"C Cortell Fuster","year":"2021","unstructured":"Cortell Fuster C, Mart\u00ednez G\u00f3mez MA, Cerc\u00f3s Lleti AC, Climente MM. Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence. J Dermatolog Treat. 2021. https:\/\/doi.org\/10.1080\/09546634.2021.1905768.","journal-title":"J Dermatolog Treat"},{"key":"2496_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2020.00001","volume":"7","author":"T Okanishi","year":"2020","unstructured":"Okanishi T, Fujimoto A, Enoki H, Ogai M. Early sirolimus gel treatment may diminish angiofibromas and prevent angiofibroma recurrence in children with tuberous sclerosis complex. Front Med. 2020;7:1 (Lausanne).","journal-title":"Front Med"},{"key":"2496_CR40","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/pde.12933","volume":"33","author":"C Crall","year":"2016","unstructured":"Crall C, Valle M, Kapur K, Dies KA, Liang MG, Sahin M, et al. Effect of angiofibromas on quality of life and access to care in tuberous sclerosis patients and their caregivers. Pediatr Dermatol. 2016;33:518\u201325.","journal-title":"Pediatr Dermatol"},{"key":"2496_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2016.04.003","volume":"61","author":"S J\u00f3\u017awiak","year":"2016","unstructured":"J\u00f3\u017awiak S, Sadowski K, Kotulska K, Schwartz RA. Topical use of mammalian target of rapamycin (mTOR) inhibitors in tuberous sclerosis complex-a comprehensive review of the literature. Pediatr Neurol. 2016;61:21\u20137.","journal-title":"Pediatr Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02496-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02496-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02496-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T19:06:02Z","timestamp":1663182362000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02496-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2496"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02496-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"8 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Natural History Database is managed and maintained by the TSC Alliance, MD, USA, data were de-identified, and no ethics committee approval was sought. Statistical analysis was performed on the de-identified data. The views expressed in this article are those of the authors and do not necessarily reflect the opinion of the TSC Alliance.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and Consent to participate"}},{"value":"SB and EB are employees of Nobelpharma America, LLC. SR and JN are employees of TSC Alliance, a non-profit organization which reports revenue from individual donors and corporations including Aeovian, Jazz Pharmaceuticals, BridgeBio, LivaNova, Lundbeck, Mallinckrodt, MassMutual, Neurelis, Nobelpharma America, Novartis, Ovid, UCB, and Upsher-Smith.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"355"}}